Lexaria Bioscience Corp.’s disruptive patented technology DehydraTECH™ is available to be licensed by both the consumer-packaged goods industry as well as the drug and pharmaceutical industry. DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:
Consumer Packaged Goods
Capsules, Pills and Tablets
Testing DehydraTECH in the Real World
DehydraTECH is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system. The technology has demonstrated affinity for transdermal applications and demonstrated effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has a proven track record of, and is actively conducting in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of APIs through ingestible means. Test data consistently shows that DehydraTECH reduces the time required to enter the bloodstream, increases absorption rate, and also improves the taste and smell of edible products.
For more information on study results, visit our Research page
Potential Benefits of DehydraTECH
Partnering with Industry Experts to Implement DehydraTECH Across Many Fields
Lexaria has demonstrated its ability to enter formal agreements with Fortune 100 companies, and we will continue to foster new partnerships.
We are actively developing lead product pipeline candidates in the areas of:
CBD for hypertension and potentially heart disease
Lexaria engages strategic partnerships with third party companies interested in exploring formulation opportunities with their specific APIs of interest.
We also out-license our technology in exchange for up-front fees, milestone payments and/or royalty payments, and we offer dietary supplement GMP-grade intermediate formulations to corporate clients on a toll processing basis.